High Efficacy Combined Microneedles Array with Methotrexate Nanocrystals for Effective Anti-Rheumatoid Arthritis
Fang Wei,Qiuyue Wang,Hang Liu,Xuejing Yang,Wenyu Cao,Weiman Zhao,Yingying Li,Lijie Zheng,Tao Ma,Qingqing Wang
DOI: https://doi.org/10.2147/IJN.S365523
IF: 7.033
2022-05-25
International Journal of Nanomedicine
Abstract:Fang Wei, 1 Qiuyue Wang, 1 Hang Liu, 1 Xuejing Yang, 1 Wenyu Cao, 1 Weiman Zhao, 1 Yingying Li, 1 Lijie Zheng, 1 Tao Ma, 1, 2 Qingqing Wang 1– 3 1 School of Pharmacy, Bengbu Medical College, Bengbu, Anhui Province, 233030, People's Republic of China; 2 Engineering Research Center for Biochemical Pharmaceuticals of Anhui Province, Bengbu Medical College, Bengbu, Anhui Province, 233030, People's Republic of China; 3 Bengbu BBCA Medical Science Co., Ltd., Bengbu, Anhui Province, 233030, People's Republic of China Correspondence: Qingqing Wang; Tao Ma, School of Pharmacy, Bengbu Medical College, Bengbu, Anhui Province, 233030, People's Republic of China, Tel +86 15605528300 ; +86 13855266592, Email ; Introduction: Methotrexate (MTX) is the first-line drug for the treatment of rheumatoid arthritis (RA) in several countries. However, MTX has an extremely low solubility in water, and the side effects caused by its delivery mode restrict its curative effect. In this study, we designed a dissolving microneedles array (DMNA) containing MTX nanocrystals (MTX-NCs) () to improve the treatment of RA. DMNA-based drug delivery combines the advantages of patient compliance with the use of transdermal drug delivery systems and high-efficiency injection administration; thus, it can mitigate the side effects that result from current administration routes. Carrier-free and surfactant-free MTX-NCs were prepared to overcome bioavailability limitations and poor drug loading problems. Methods: The MTX-NCs prepared by reverse solvent precipitation method was encapsulated in the DMNA. The morphology, mechanical properties, safety, stability and in vivo dissolution were evaluated, and its pharmacodynamic characteristics were assessed in a rat model of RA. Results: The particle size of the MTX-NCs was 148.1 ± 10.1 nm. The were found to be rigid enough to penetrate the skin and deliver the drug successfully. The results indicated effective skin recovery after removal of the DMNA. It was found that the significantly reduced foot swelling in the rats and regulated the balance in the levels of related cytokines. It also reduced pathological damage to the synovium, joint, and cartilage, and effectively alleviated organ injury in the rats. Conclusion: Transdermal administration of may be an effective approach for treating RA. Graphical Keywords: nanocrystals, inflammation, dissolving microneedles array, transdermal, rheumatoid arthritis Graphical Rheumatoid arthritis (RA) is a systemic and chronic autoimmune disease. 1,2 Its main pathological features include proliferation of synovial lining cells, many inflammatory cells in the stroma, proliferation of microvessels, formation of pannus, and destruction of cartilage and bone structure, which can result in joint deformity and loss of function. Consequently, patients with RA experience great pain and suffering. 3–5 At present, there are several drugs for the clinical treatment of RA, which include non-steroidal anti-inflammatory drugs, glucocorticoids, and disease-modifying antirheumatic drugs. 6 Methotrexate (MTX) is an antirheumatic drug that can continuously alleviate the symptoms of RA, inhibit progressive damage to tissues and joints, and delay or prevent the development of the disease. It has been widely used in the clinical treatment of RA. 7–9 The main dosage forms of MTX that are used clinically are tablets and injections. 10–13 Long-term oral administration of MTX can result in adverse reactions such as digestive tract problems, 14,15 myelosuppression, 16,17 and abnormal liver and kidney function. 18,19 Moreover, MTX injection must be administered by healthcare professionals and the needles used are a biohazard. The injection is also inconvenient for patients and can cause pain and bleeding. 20–23 Therefore, to overcome the above shortcomings associated with the administration of MTX tablets and injections, it is necessary to develop a new dosage form that can be administered via an alternative route. The dissolving microneedles array (DMNA) 24–26 is composed of water-soluble and active drugs. After administration, microneedles (MNs) inserted into the skin dissolve rapidly to efficiently release the drug they contain. This mode of drug administration is effective and can be used to achieve the same delivery efficiency of an injection. It can also avoid the damage to rich nerve endings and capillaries in the dermis by larger needles, 27,28 which can reduce or eliminate pain and infection. Additionally, the use -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology